A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. (Q45731131)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Sophie Park

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Nicolas Chapuis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Jerome Tamburini

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Norbert Ifrah

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Didier Bouscary

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

F Saint Marcoux

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

C Recher

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

P Chevallier

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

J-Y Cahn

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

T Leguay

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

P Bories

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

F Witz

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

T Lamy

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

P Mayeux

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

C Lacombe

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

C Demur

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

A Merlat

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

R Delepine

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

N Vey

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

F Dreyfus

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

M C Béné

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

GOELAMS (Groupe Ouest Est d’Etude des Leucémies aiguës et Autres Maladies du Sang)

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

16 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

1479-1486

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

Independent prognostic variables in acute myeloid leukaemia

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Antileukemic activity of rapamycin in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

mTOR, a new therapeutic target in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Survival of acute myeloid leukemia cells requires PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

mTOR regulates cell survival after etoposide treatment in primary AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 tri

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a prospective multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

High-dose ara-C and etoposide in refractory or relapsing acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Growth factors in acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Long-term survival and late relapses in acute leukaemia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Late relapses in acute myeloid leukemia: analysis of characteristics and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3- mutated acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

7 January 2021

https://api.crossref.org/works/10.1038%2FLEU.2013.17

1 reference

7 January 2021

Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

7 January 2021

Very late recurrences of leukemia: Why does leukemia awake after many years of dormancy?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.17

7 January 2021

Identifiers

DOI

10.1038/LEU.2013.17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23321953%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

22 February 2020

1035660563

0 references

Fatcat ID

release_yir62ptyfzejlanku2mfwpxfym

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yir62ptyfzejlanku2mfwpxfym

24 November 2022

mapped directly with Wikidata item

1 reference